Market Research Logo

Non-small Cell Lung Cancer (NSCLC) Therapeutics Market Analysis By Drug (Alimta, Iressa, Avastin, Tarceva, Zykadia, Tagrisso, Xalkori, Cyramza, Opdivo, Alecensa), By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts,

Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Non-small Cell Lung Cancer Therapeutics Market Variables, Trends & Scope
3.1 Market Segmentation and Scope
3.1.1 Market driver analysis
3.1.1.1 Strong pipeline
3.1.1.2 Rising prevalence of NSCLC
3.1.2 Market restraint analysis
3.1.2.1 Pricing pressure
3.2 Penetration & Growth Prospects Mapping
3.3 Non-small Cell Lung Cancer Therapeutics Market - PESTLE Analysis
3.4 Industry Analysis - Porter’s
3.5 Non-small Cell Lung Cancer Therapeutics Competitive Scenario, 2015
3.5.1 Competitive landscape: Market position analysis (based on product portfolio, regional presence and strategic initiatives)
Chapter 4 Non-small Cell Lung Cancer Therapeutics: Drug Estimates & Trend Analysis
4.1 Global Non-small Cell Lung Cancer Therapeutics Market: Drug Movement Analysis & Market Share, 2016 & 2025
4.2 Alimta
4.2.1 Alimta market estimates and forecasts, 2014 - 2025 (USD Million)
4.3 Iressa
4.3.1 Iressa market estimates and forecasts, 2014 - 2025 (USD Million)
4.4 Avastin
4.4.1 Iressa market estimates and forecasts, 2014 - 2025 (USD Million)
4.5 Tarceva
4.5.1 Tarceva market estimates and forecasts, 2014 - 2025 (USD Million)
4.6 Zykadia
4.6.1 Zykadia market estimates and forecasts, 2014 - 2025 (USD Million)
4.7 Tagrisso
4.7.1 Tagrisso market estimates and forecasts, 2014 - 2025 (USD Million)
4.8 Xalkori
4.8.1 Xalkori market estimates and forecasts, 2014 - 2025 (USD Million)
4.9 Cyramza
4.9.1 Cyramza market estimates and forecasts, 2014 - 2025 (USD Million)
4.10 Opdivo
4.10.1 Opdivo market estimates and forecasts, 2014 - 2025 (USD Million)
4.11 Alecensa
4.11.1 Alecensa market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 5 Non-small Cell Lung Cancer Therapeutics: Regional Estimates & Trend Analysis
5.1 Regional Movement Analysis & Market Share, 2016 & 2025
5.2 North America
5.2.1 North America non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.2.2 North America non-small cell lung cancer therapeutics market, by country, 2014 - 2025 (USD Million)
5.2.3 U.S.
5.2.3.1 U.S. non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.2.4 Canada
5.2.4.1 Canada non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.3 Europe
5.3.1 Europe non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.3.2 Europe non-small cell lung cancer therapeutics market, by country, 2014 - 2025 (USD Million)
5.3.3 Germany
5.3.3.1 Germany non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.3.4 UK
5.3.4.1 UK non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.4 Asia Pacific
5.4.1 Asia Pacific non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.4.2 Asia Pacific non-small cell lung cancer therapeutics market, by country, 2014 - 2025 (USD Million)
5.4.3 Japan
5.4.3.1 Japan non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.4.5 China
5.4.5.1 China non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.5 Latin America
5.5.1 Latin America non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.5.2 Latin America non-small cell lung cancer therapeutics market, by country, 2014 - 2025 (USD Million)
5.5.3 Brazil
5.5.3.1 Brazil non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.5.4 Mexico
5.5.4.1 Mexiconon-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.6 MEA
5.6.1 MEA non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.6.2 MEA non-small cell lung cancer therapeutics market, by country, 2014 - 2025 (USD Million)
5.6.3 South Africa
5.6.3.1 South Africa non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
Chapter 6 Competitive Landscape
7.1 GlaxoSmithKline (GSK) Plc
7.1.1 Company overview
7.1.2 Financial performance
7.1.3 Product benchmarking
7.1.4 Strategic initiatives
7.2 Novartis
7.2.1 Company overview
7.2.2 Financial performance
7.2.3 Product benchmarking
7.2.4 Strategic initiatives
7.3 AstraZeneca
7.3.1 Company overview
7.3.2 Financial performance
7.3.3 Product benchmarking
7.3.4 Strategic initiatives
7.4 F. Hoffmann-La Roche Ltd
7.4.1 Company overview
7.4.2 Financial performance
7.4.3 Product benchmarking
7.4.4 Strategic initiatives
7.5 Bristol Myers Squibb Company
7.5.1 Company overview
7.5.2 Financial performance
7.5.3 Product benchmarking
7.5.4 Strategic initiatives
7.6 Pfizer, Inc.
7.6.1 Company overview
7.6.2 Financial performance
7.6.3 Product benchmarking
7.6.4 Strategic Initiatives
7.7 Eli Lilly and Company
7.7.1 Company overview
7.7.2 Financial performance
7.7.3 Product benchmarking
7.7.4 Strategic initiatives
7.8 Sanofi
7.8.1 Company overview
7.8.2 Financial performance
7.8.3 Product benchmarking
7.8.4 Strategic initiatives
List of Tables
TABLE 1 Non-small cell cancer therapeutics market - global market current and forecast by regions (2015 - 2024) in (USD Million)
TABLE 2 North America non-small cell cancer therapeutics market estimates and forecasts, by country, 2014 - 2025 (USD Million)
TABLE 3 North America non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
TABLE 4 U.S. non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
TABLE 5 Canada non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
TABLE 6 Europe non-small cell cancer therapeutics market estimates and forecasts, by country, 2014 - 2025 (USD Million)
TABLE 7 Europe non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
TABLE 8 UK non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
TABLE 9 Germany non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
TABLE 10 Asia Pacific non-small cell cancer therapeutics market estimates and forecasts, by country, 2014 - 2025 (USD Million)
TABLE 11 Asia Pacific non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
TABLE 12 Japan non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
TABLE 13 China non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
TABLE 14 Latin America non-small cell cancer therapeutics market estimates and forecasts, by country, 2014 - 2025 (USD Million)
TABLE 15 Latin America non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
TABLE 16 Brazil non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
TABLE 17 Mexico non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
TABLE 18 MEA non-small cell cancer therapeutics market estimates and forecasts, by country, 2014 - 2025 (USD Million)
TABLE 19 MEA non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
TABLE 20 South Africa non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
List of Figures
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & Forecasting
FIG. 6 QFD modeling for market share assessment
FIG. 7 Market summary
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 Penetration & growth prospect mapping
FIG. 13 Non-small cell lung cancer therapeutics market - PESTLE analysis
FIG. 14 Porter’s Five Forces Analysis
FIG. 15 Non-small cell lung cancer therapeutics market outlook key takeaways
FIG. 16 Non-small cell lung cancer therapeutics market: drug movement analysis
FIG. 17 Global non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
FIG. 18 Global Alimta market, 2014 - 2025 (USD Million)
FIG. 19 Global Iressa market, 2014 - 2025 (USD Million)
FIG. 20 Global Avastin market, 2014 - 2025 (USD Million)
FIG. 21 Global Tarceva market, 2014 - 2025 (USD Million)
FIG. 22 Global Zykadia market, 2014 - 2025 (USD Million)
FIG. 23 Global Tagrisso market, 2014 - 2025 (USD Million)
FIG. 24 Global Xalkori market, 2014 - 2025 (USD Million)
FIG. 25 Global Cyramza market, 2014 - 2025 (USD Million)
FIG. 26 Global Opdivo market, 2014 - 2025 (USD Million)
FIG. 27 Global Alecensa market, 2014 - 2025 (USD Million)
FIG. 28 Regional market: Key takeaways
FIG. 29 Non-small cell lung cancer therapeutics market regional outlook, 2015 & 2025
FIG. 30 North America non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
FIG. 31 U.S. non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
FIG. 32 Canada non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
FIG. 33 Europe non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
FIG. 34 Germany non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
FIG. 35 UK non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
FIG. 36 Asia Pacific non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
FIG. 37 Japan non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
FIG. 38 China non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
FIG. 39 Latin America non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
FIG. 40 Brazil non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
FIG. 41 Mexico non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
FIG. 42 Middle East Africa non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
FIG. 43 South Africa non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
FIG. 44 Strategy frameworks

Non-small Cell Lung Cancer (NSCLC) Therapeutics Market Analysis By Drug (Alimta, Iressa, Avastin, Tarceva, Zykadia, Tagrisso, Xalkori, Cyramza, Opdivo, Alecensa), By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2014 - 2025

The global non-small cell lung cancer therapeutics market is expected to reach a value of USD 12.2 billion by 2025, based on a new report by Grand View Research, Inc. The non-small cell cancer therapeutics (NSCLC) market is anticipated to witness significant growth during the forecast period. This can be attributed to the high investment by market players in the research and development of lung cancer therapy, presence of a rich pipeline, and increasing penetration of drugs during the forecast period.

Introduction of several drugs in various geographical regions is likely to drive the market during the forecast period. For instance, in October 2016, the FDA granted Breakthrough Therapy Designation to Alecensa (alectinib), a drug developed by Genentech to treat ALK-positive NSCLC as a first-line treatment. The drug has been approved in the U.S., Japan, Canada, Hong Kong, South Korea, Kuwait, and Israel.

Presence of a strong pipeline of drugs for non-small cell lung cancer helps propel the market during the forecast period. Bristol-Myers Squibb Company, Orion Corporation, Merck KGaA, AstraZeneca, F. Hoffmann-La Roche Ltd, and Pfizer, Inc. have major molecules in the pipeline.

Further key findings from the study suggest:

By drug, Alimta accounted for the highest share in 2015. However, it is expected to witness decline in its share during the forecast period.

Alecensa (alectinib) is expected to grow at the highest rate during the forecast period. This is majorly attributed to the clinical benefit of the drug to treat ALK-positive NSCLC.

Alecensa is expected to be a competitor to Pfizer’s Xalkori and Merck’s Keytruda during the forecast period. A superior progression-free survival rate of Alecensa was observed in the clinical trials as compared to Crizotinib.

Geographically, North America dominated the overall industry in 2015. This is due to the early entry of drugs in the market, increased adoption of new treatment, and high cost of the drug.

It is expected that North America would maintain its dominance during the forecast period and grow with the highest rate over the coming years due to expected entry of new drugs.

Several players are operating in the industry. Geographical penetration and development of innovative & effective drugs are the key strategies of the players to increase their share.

Some of the key players are GlaxoSmithKline (GSK) Plc., Novartis AG, AstraZeneca, F. Hoffmann-La Roche AG, Bristol-Myers Squibb, Pfizer Inc., Eli Lilly & Company, and Sanofi.


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;